Skip to main content
PMC home page
Acta Neuropathologica Communications logoLink to Acta Neuropathologica Communications
. 2023 Jul 12;11:116. doi: 10.1186/s40478-023-01600-2

Correction to: Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators

Berta Segura-Collar 1,2, Sara Hiller-Vallina 1,2, Olaya de Dios 1,3, Marta Caamaño-Moreno 1,2, Lucia Mondejar-Ruescas 1,2, Juan M Sepulveda-Sanchez 1,4, Ricardo Gargini 1,2,4,✉
PMCID: PMC10337095  PMID: 37438824

Acta Neuropathologica Communications (2023) 11:79

10.1186/s40478-023-01569-y

Following publication of the original article [1], the authors reported incorrect information in the ‘Acknowledgements’ section.

The first part of the ‘Acknowledgements’ section originally read: Work was supported by Ministerio de Ciencia e Innovación and FEDER funds: CP21/00116 and PI22/01171 to RG.

The sentence should read: This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project “CP21/00116 and PI22/0117” and co-funded by the European Union to RG.

The original article [1] has been updated.

Footnotes

The online version of the original article can be found at 10.1186/s40478-023-01569-y.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Segura-Collar et al. Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators. Acta Neuropathologica Communications (2023) 11:79. 10.1186/s40478-023-01569-y. [DOI] [PMC free article] [PubMed]

Articles from Acta Neuropathologica Communications are provided here courtesy of BMC

RESOURCES